Related Experiment Video
Updated: Aug 5, 2026
07:23
Using High Content Imaging to Quantify Target Engagement in Adherent Cells
Published on: November 29, 2018
Targeted Affinity Screening Approach for Bioactive Compounds in Curcuma longa Utilizing a Cell-Functionalized
Meihui Zhang1,2, Xiaxi Zhang1,2, Xinyue Yang1,2
1School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an710061, China.
Analytical Chemistry
|July 27, 2026
Summary
Researchers developed a novel 3D biomimetic screening method using cells to identify natural compounds that bind to alpha-1A adrenergic receptors (AR). This approach successfully identified potential prostate-relaxing and antiproliferative compounds from Curcuma longa extracts.
Area of Science:
- Pharmacology
- Biochemistry
- Analytical Chemistry
Background:
- Selective discovery of receptor-binding ligands from complex natural products is challenging.
- Existing methods often struggle to maintain native receptor integrity and cellular architecture.
Purpose of the Study:
- To establish a novel three-dimensional (3D) biomimetic screening strategy for receptor-guided ligand discovery.
- To identify bioactive compounds targeting the alpha-1A adrenergic receptor (α1A-AR) from natural sources.
Main Methods:
- Developed a 3D biomimetic stationary phase using cells with high α1A-AR expression embedded in an agarose network.
- Screened Curcuma longa extracts using the cell-based 3D biomimetic system.
- Validated identified compounds through subsequent bioassays.
Main Results:
- Successfully preserved native cellular architecture and membrane receptor integrity within the 3D microenvironment.
- Identified ar-turmerone, curcumin, and curcumin III as α1A-AR binding candidates from Curcuma longa.
- Demonstrated prostate relaxation and antiproliferative activities of the identified compounds.
Conclusions:
- The established 3D biomimetic strategy is effective for receptor-guided ligand screening from complex natural matrices.
- This cell-based bioanalytical platform expands capabilities for bioactive compound and lead discovery.
